A Sliding Share Price Has Us Looking At Trulieve Cannabis Corp.’s (CSE:TRUL) P/E Ratio

Unfortunately for some shareholders, the Trulieve Cannabis (CSE:TRUL) share price has dived 34% in the last thirty days. Indeed the recent decline has arguably caused some bitterness for shareholders who have held through the 44% drop over twelve months.

All else being equal, a share price drop should make a stock more attractive to potential investors. While the market sentiment towards a stock is very changeable, in the long run, the share price will tend to move in the same direction as earnings per share. The implication here is that long term investors have an opportunity when expectations of a company are too low. One way to gauge market expectations of a stock is to look at its Price to Earnings Ratio (PE Ratio). A high P/E implies that investors have high expectations of what a company can achieve compared to a company with a low P/E ratio.

See our latest analysis for Trulieve Cannabis

How Does Trulieve Cannabis’s P/E Ratio Compare To Its Peers?

We can tell from its P/E ratio of 4.87 that sentiment around Trulieve Cannabis isn’t particularly high. The image below shows that Trulieve Cannabis has a lower P/E than the average (10.2) P/E for companies in the pharmaceuticals industry.

CNSX:TRUL Price Estimation Relative to Market, March 13th 2020
CNSX:TRUL Price Estimation Relative to Market, March 13th 2020

This suggests that market participants think Trulieve Cannabis will underperform other companies in its industry. Since the market seems unimpressed with Trulieve Cannabis, it’s quite possible it could surprise on the upside. You should delve deeper. I like to check if company insiders have been buying or selling.

How Growth Rates Impact P/E Ratios

Generally speaking the rate of earnings growth has a profound impact on a company’s P/E multiple. When earnings grow, the ‘E’ increases, over time. And in that case, the P/E ratio itself will drop rather quickly. So while a stock may look expensive based on past earnings, it could be cheap based on future earnings.

In the last year, Trulieve Cannabis grew EPS like Taylor Swift grew her fan base back in 2010; the 338% gain was both fast and well deserved.

Remember: P/E Ratios Don’t Consider The Balance Sheet

The ‘Price’ in P/E reflects the market capitalization of the company. Thus, the metric does not reflect cash or debt held by the company. The exact same company would hypothetically deserve a higher P/E ratio if it had a strong balance sheet, than if it had a weak one with lots of debt, because a cashed up company can spend on growth.

Such spending might be good or bad, overall, but the key point here is that you need to look at debt to understand the P/E ratio in context.

Trulieve Cannabis’s Balance Sheet

Trulieve Cannabis has net debt worth just 6.8% of its market capitalization. It would probably trade on a higher P/E ratio if it had a lot of cash, but I doubt it is having a big impact.

The Bottom Line On Trulieve Cannabis’s P/E Ratio

Trulieve Cannabis has a P/E of 4.9. That’s below the average in the CA market, which is 11.6. The company hasn’t stretched its balance sheet, and earnings growth was good last year. If the company can continue to grow earnings, then the current P/E may be unjustifiably low. What can be absolutely certain is that the market has become more pessimistic about Trulieve Cannabis over the last month, with the P/E ratio falling from 7.4 back then to 4.9 today. For those who prefer to invest with the flow of momentum, that might be a bad sign, but for deep value investors this stock might justify some research.

Investors should be looking to buy stocks that the market is wrong about. If the reality for a company is not as bad as the P/E ratio indicates, then the share price should increase as the market realizes this. So this free report on the analyst consensus forecasts could help you make a master move on this stock.

Of course you might be able to find a better stock than Trulieve Cannabis. So you may wish to see this free collection of other companies that have grown earnings strongly.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.